Acquisition of Ordinary Shares pursuant to a vesting under the AstraZeneca Performance Share Plan, for nil consideration. of 11,133 shares at
AstraZeneca PLC
19 August 2026
19 August 2026
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that, on 17 August 2026, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to the Company's Chief Financial Officer, Dr Aradhana Sarin, under the AstraZeneca Performance Share Plan (the AZPSP).
The award of shares under the AZPSP was granted on 13 August 2021 and was subject to a combination of performance measures focused on scientific, commercial and financial performance assessed over a three-year period. On the third anniversary of grant, the award was placed in a two-year holding period. The award vested at the end of that holding period. This is the first PSP award to vest for Dr Sarin following her appointment as Chief Financial Officer of the Company in 2021.
Following the reinvestment of dividends accrued during performance and holding periods of the AZPSP award, and the withholding of shares to satisfy certain tax obligations arising on vesting, the Dr Sarin's beneficial interests in Ordinary Shares changed as detailed in the table below:
|
PDMR |
Position |
Ordinary Shares acquired
|
|
Aradhana Sarin |
Executive Director and Chief Financial Officer |
11,133 |
For tax purposes, the fair market value of an Ordinary Share at vest of the AZPSP award was £114.60, being the closing price on the last trading day preceding the vesting.
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Aradhana Sarin |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Financial Officer |
||||
|
b)
|
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
AstraZeneca PLC |
||||
|
b)
|
LEI |
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 |
||||
|
b)
|
Nature of the transaction |
Acquisition of Ordinary Shares pursuant to a vesting under the AstraZeneca Performance Share Plan, for nil consideration. |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information - Aggregated volume - Price |
Not applicable - single transaction |
||||
|
e) |
Date of the transaction |
17 August 2026 |
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.